TC A101
Alternative Names: anti-ALPP CAR-T cells - TCRCure Biopharma; CARs-T therapy - TCRCure Biotech; Retroviral vector-transduced anti-ALPP CARs-T therapy - TCRCure Biotech; TC-A101Latest Information Update: 27 Mar 2023
At a glance
- Originator TCRCure Biopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Endometrial cancer; Ovarian cancer
Most Recent Events
- 27 Mar 2023 Discontinued - Phase-I/II for Endometrial cancer (Metastatic disease) in China (Parenteral) prior to March 2023 (TCRCure Biopharma website, March 2023)
- 27 Mar 2023 Discontinued - Phase-I/II for Ovarian cancer (Metastatic disease) in China (Parenteral) prior to March 2023 (TCRCure Biopharma website, March 2023)
- 09 Sep 2022 Phase-I/II clinical trials in Endometrial cancer (Metastatic disease) in China prior to September 2022 (Parenteral) (NCT04627740)